Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-6-11
pubmed:abstractText
Cisplatin, a standard component of combination chemotherapy for several tumors, presents important anti-tumor properties but also several toxic effects. In particular, the major dose-limiting effect appears to be renal toxicity. In several countries, to reduce nephrotoxicity after cisplatin administration, a 24-h hydration is recommended following a chemotherapy treatment in a hospital regimen. In our Institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-8916
pubmed:author
pubmed:issnType
Print
pubmed:volume
93
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
138-44
pubmed:dateRevised
2008-12-12
pubmed:meshHeading
pubmed-meshheading:17557559-Adult, pubmed-meshheading:17557559-Aged, pubmed-meshheading:17557559-Ambulatory Care, pubmed-meshheading:17557559-Antineoplastic Agents, pubmed-meshheading:17557559-Cisplatin, pubmed-meshheading:17557559-Creatine, pubmed-meshheading:17557559-Female, pubmed-meshheading:17557559-Fluid Therapy, pubmed-meshheading:17557559-Furosemide, pubmed-meshheading:17557559-Humans, pubmed-meshheading:17557559-Incidence, pubmed-meshheading:17557559-Kidney Diseases, pubmed-meshheading:17557559-Lung Neoplasms, pubmed-meshheading:17557559-Male, pubmed-meshheading:17557559-Mesothelioma, pubmed-meshheading:17557559-Middle Aged, pubmed-meshheading:17557559-Randomized Controlled Trials as Topic, pubmed-meshheading:17557559-Retrospective Studies, pubmed-meshheading:17557559-Sodium Chloride
pubmed:articleTitle
Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
pubmed:affiliation
Division of Medical Oncology, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy. mtiseo@ao.pr.it
pubmed:publicationType
Journal Article